FDA extends review of Belite Bio’s tinlarebant NDA to May 2027

Belite Bio has received a three-month extension to the U.S. Food and Drug Administration review timeline for tinlarebant in Stargardt disease type 1.

The revised Prescription Drug User Fee Act action date is May 12, 2027.

Belite Bio said the extension will give the FDA additional time to review information submitted in support of the New Drug Application.

The company did not report that the agency had identified any major deficiencies in the application.

The FDA also informed Belite Bio that, if no major deficiencies are identified during the continuing review, it plans to communicate proposed labelling requests and any anticipated postmarketing requirements by April 12, 2027.

Tinlarebant, also known as LBS-008, is an investigational oral treatment being developed for Stargardt disease type 1.

The therapy is designed to reduce the accumulation of vitamin A-derived toxic by-products known as bisretinoids in the retina.

Bisretinoids are generated through the visual cycle and are believed to contribute to retinal damage in Stargardt disease and geographic atrophy associated with advanced dry age-related macular degeneration.

Tinlarebant works by reducing levels of retinol binding protein 4, the main carrier responsible for transporting vitamin A from the liver to the eye.

By limiting the amount of retinol delivered to the eye, the treatment is intended to decrease formation of bisretinoids.

Belite Bio said it remains in discussions with the FDA during the review process and continues to support the application with its existing clinical data package.

Tinlarebant has received Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations from the FDA for Stargardt disease type 1.

The therapy also holds Orphan Drug Designation in the U.S., European Union, Japan and Switzerland, as well as Sakigake Designation in Japan.

Tinlarebant is also being investigated in geographic atrophy, an advanced form of dry age-related macular degeneration.

The FDA’s revised decision date means a regulatory outcome for tinlarebant in Stargardt disease type 1 is now expected by May 12, 2027.



Related Topics and Keywords

, , , , , , , , , , , , , , , , , , , , , , ,

Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy